FII Institute announces its list of partners, representing leading global organizations from business, academia, and public policy sectors.

RIYADH, Saudi Arabia, Oct. 24, 2023 /PRNewswire/ — Leading global organisations from business, academia and public policy are supporting an ongoing programme of research, investment and platforms to address global challenges including economic stability and growth, equitable development, climate change investment, the environment, and the acceleration of technologies including AI, and their impact on education and health. 

This year’s activities will culminate in three days of focused discussion about challenges facing humanity to take place in Riyadh between 24-26 October during the FII7 conference. Over six thousand delegates including world leaders, ministers, CEOs, investors, founders and public policy experts will attend the globally-recognized platform.

The line up of FII Institute partners for 2023 is stronger than ever before. 

Alongside ‘founding partner,’ the Public Investment Fund (PIF) of Saudi Arabia, and ‘vision partner,’ the Ministry of Investment of Saudi Arabia, a group of 23 ‘strategic partners’ support the ongoing programmes, initiatives, and mission of the FII Institute throughout the year.

Aramco, Diriyah, Emaar, GFH, HSBC SAB, KAFD, Ma’aden, NEOM, New Murabba, PepsiCo, Red Sea Global, Riyad Bank, ROSHN, The Royal Commission for Al Ula, SABIC, Sanabil Investments, Saudi Electricity Company, SNB, SoftBank Vision Fund, Standard Chartered, State Street, stc, THIQAH, and Vision Invest as strategic partners of FII Institute and its programmes.

‘FII7 Partners’ include Dr. Sulaiman Alhabib and SAUDIA.

Insights, thinking, and dedicated panel discussions are supported by ‘knowledge partners’, from leading consultancies, universities and institutions: Accenture, Bain & Company, BCG, Deloitte, EY, the Bill and Melinda Gates Foundation, Gavi, The Global Fund, Kearny, KPMG, McKinsey, Nature, Strategy&, and UNICEF.

‘Academic partners,’ including King Abdullah University of Science and Technology (KAUST) and Stanford University, will be contributing to the discussion and to the FII Institute’s year-long programmes.

Richard Attias, CEO of the Future Investment Initiative Institute said:

"Our partners are what make the FII Institute community so impactful. Every year our line-up of partners goes from strength to strength. This year, we are proud to recognise partners from 42 leading global corporations, universities and institutions. Our partners reflect an unparalleled concentration of great minds and leaders, and alongside this community, the Institute is making strides towards our only agenda: Impact on Humanity."

About the Future Investment Initiative Institute

The Future Investment Initiative (FII) Institute is a global non-profit foundation driven by data with an investment arm and one agenda: Impact on Humanity. Global and inclusive, we foster great minds from around the world and turn ideas into real-world solutions in four critical areas: Artificial Intelligence (AI) & Robotics, Education, Healthcare and Sustainability.

Source : FUTURE INVESTMENT INITIATIVE INSTITUTE ANNOUNCES ITS LIST OF GLOBAL PARTNERS AHEAD OF THE FII7 CONFERENCE

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

IBIZA, Spain, Oct. 24, 2023 /PRNewswire/ — Dahua Technology, a world-leading video-centric AIoT solution and service provider, recently held its 5th Partner Day in Ibiza, Spain. Under the theme "Think# as One", the event highlighted Dahua’s dedication to expanding partnerships in multiple fields, jointly creating a mutually beneficial and win-win ecosystem for the sustainable development of the AIoT industry.

The Partner Day demonstrated Dahua’s dedication to innovation, collaboration, cybersecurity, and the advancement of AIoT solutions. It served as a prominent platform that connects key industry players to explore new breakthroughs and opportunities, and empower various industries through technology integration and joint solutions.

The grand event witnessed the presence of more than 370 distinguished leaders and representatives from key sectors such as cybersecurity, smart city, transportation, retail, energy, and education across Europe. In addition to technical partners, this event also brings together system integrators, end users, and organizations from various fields.

Mr. David Shen, President of Dahua WEU, opened the event by expressing his gratitude to the attendees. His opening remarks delivered the core message of comprehensive collaboration with diverse fields including hardware, software, training, certification and delivery, working as one to create a more inclusive ecosystem.

In the following keynote speech, Mr. Neil Ni, Vice President of Dahua Global Business, emphasized the importance of partnerships with ecosystem collaborators and their role in facilitating innovation and mutual growth in the ever-evolving digital landscape. Aligning with the company’s business strategy and core AIoT capabilities, Mr. Ni outlined Dahua’s ecosystem strategy in three key dimensions: awareness, framework, and operation, and how these contribute to the success of both industry customers and ecosystem partners. He stressed that Dahua will further deepen its ecosystem and open up capabilities at multiple levels including business, technology, and services to enhance experience and benefits of partners. "By combining our strengths, we can co-create value-driven solutions that transcend boundaries and address complex challenges. Through mutual empowerment, we can expand market reach, enhance product portfolios, and achieve sustainable growth that benefits all stakeholders," he concluded.

Mr. Nash Zhang, Managing Director of Dahua Global Enterprise Business mentioned EU’s accelerated digital transformation in four key areas, including infrastructure construction, enterprise transformation, public services, and talent cultivation. He went on to share Dahua’s application projects in aiding the digital transformation of industrial parks, education, and energy enterprises, as well as its active participation in low-carbon zone management in Spain, which has a positive impact on a safe, efficient, and green future.

Furthermore, a roundtable discussion regarding digital education was conducted among distinguished experts in the education industry, delving into the challenges and trends in different countries, the level of digitalization and IT, the balance of educational resources, and the advantages of online classrooms. It provided valuable insights for the development of a high-performing digital education ecosystem in Europe.

The event also showcased insights into Dahua’s commitment to cybersecurity. These include an informative presentation from SGS Brightsight focusing on Dahua’s Common Criteria EAL2 and EAL3 assessment and certification, as well as an in-depth outlook at Dahua’s thermal imaging product testing project shared by CNPP. "Cybersecurity is Dahua’s top priority. We have been exploring and applying industry best practices to ensure the security of our products and customer privacy and data. We will continue to consolidate our security capabilities, strengthen deep cooperation with third-party organizations like SGS Brightsight and CNPP, to help customers comply with GDPR and better respond to today’s cybersecurity challenges," said Mr. Shen.

As one of the most important strategic initiatives of the company, Dahua always values open and comprehensive cooperation, committed to creating value for its partners, growing together with them, and contributing to their greater success. As the digital landscape continues to evolve, Dahua will remain dedicated to empowering various industries through technology integration and joint solutions, contributing to a green, safe, and efficient digital world together.

Source : Dahua Held Its 5th Partner Day to Foster an Inclusive and Collaborative Ecosystem

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

SINGAPORE, Oct. 24, 2023 /PRNewswire/ — Cactus Custody™,  the qualified institutional digital assets custodian service provider of Matrixport, has announced an upgrade of its USD 50 million insurance for its customers with protection now extended to include crime coverage, specifically for warm wallets.

The insurance is issued by OneInfinity by OneDegree, the first and only direct insurer for digital assets in Asia. In addition to enjoying additional insurance coverage, clients have the assurance of the group having passed and met the due diligence standards to be insured by one of the world’s largest crypto insurers.

Wendy Jiang, Head of Cactus Custody, said: "We are delighted to partner with OneDegree and one of the largest Lloyd’s of London syndicates to secure enhanced coverage that includes crime. The added protection meaningfully differentiates our offering, particularly for institutions with compulsory insurance requirements, and reflects our ongoing commitment towards industry best practices."

Cactus Custody™ solutions safeguard digital assets for over 200 institutional clients with the highest level of service standards for institutions. The USD 50 million crime and specie insurance coverage is specifically tailored to Cactus Custody™ risk requirements to enhance protection of client’s assets like employee collusion, third party theft and the physical loss or damage of private keys.

Alvin Kwock, CEO of OneDegree Group, said: "Our team has worked very closely with the Matrixport team over the past weeks. Throughout the comprehensive cyber security review and technical underwriting process, we are particularly impressed by Cactus Custody’s cutting-edge system,  security design, and vault infrastructure built across three continents. With our unwavering  commitment to help the good actors in Web 3 thrive, we are glad to provide USD $50 million crime and specie capacity for cold and warm storage, backed by a reinsurance capacity rated A+ by Standard & Poor’s."

The insurance coverage includes major cryptocurrencies and NFTs, and will continue to expand as Cactus Custody™ extends support to more types of digital assets in the future.

About Cactus Custody™

Cactus Custody™ is the world’s first MetaMask Institutional (MMI) integrated custodian. It aims to provide the digital era with secure, transparent, and efficient institutional custodial services.

Built with enterprise-grade crypto management features and value-added financial services backed by cutting-edge system security design and infrastructure, its custody services cater for a wide range of business scenarios. It provides services to the world’s largest and most renowned mining companies, mining pools, cloud mining platforms, exchanges, funds and OTC dealers, supporting clients to grow and scale in a secure way.

Cactus Custody is a qualified custodian and a Hong Kong Trust Company that meets the capital reserve requirement and acts within regulatory and AML guidelines.

About Matrixport

Matrixport is one of the world’s largest and most trusted digital assets financial services ecosystem. The company’s services include prime brokerage, Cactus Custody™, spot OTC, fixed income, structured products, lending as well as asset management. Matrixport serves individuals as well as over 500 institutions across Asia and Europe. For more information, please visit www.matrixport.com.

About OneInfinity by OneDegree

OneInfinity by OneDegree offers tech-enabled digital asset insurance and risk management solutions globally. By offering tailor-made insurance to end-to-end digital asset players (including trading platforms, custodians, asset managers, banks, family offices and technology providers), OneDegree strengthens its clients’ competitive edge by enabling them to implement best practices under a robust risk management framework and secure a safety net for their assets under custody.

OneInfinity is enabled by first-in-class cybersecurity technology offered by Cymetrics, a sister company of OneDegree. OneInfinity insurance solutions bundle services offered by Cymetrics, which examine the security of clients in terms of exposure to cyber, blockchain and digital asset risks from the perspective of hackers.

OneInfinity solutions include digital asset wallet insurance (crime, and specie) and corporate liability coverages (Professional Indemnity, Directors & Officers, Investment Management and Cyber).

For more information, visit https://oneinfinity.global/

Source : Matrixport's Cactus Custody Enhances USD 50M Protection for Digital Assets to include crime and warm wallet coverage with Insurer OneDegree

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

TAIZHOU, China, Oct. 24, 2023 /PRNewswire/ — From October 19 to 22, the 14th China (Taizhou) International Pharmaceutical Fair, sponsored by the China Chamber of International Commerce and hosted by the Taizhou Municipal People’s Government and Jiangsu Branch of the China Council for the Promotion of International Trade, was successfully held in Taizhou China Pharmaceutical City. As an innovative vaccine company with independent research and development technology as the core driving force, Recbio (02179.HK) presented at Booth C18 in Hall E1-2 with three technology platforms of new adjuvants, protein engineering, immune evaluation, and heavy product pipeline. Once exhibited, it attracted the attention of a large number of experts and scholars in the pharmaceutical industry domestic and overseas, and won wide praise on the site，creating new heights and heat.

The theme of this year’s exhibition is "New adjuvants, open and win-win situation, taking root in the China Pharmaceutical City, and going to the world".

During the opening ceremony, Dr. Liu Yong, founder, Chairman of the Board and general manager of Recbio, attended the initiative and establishment ceremony of the Biomedical Industry Supply Chain Alliance and read the proposal. The alliance will gather the strength of all parties and strive to seek the "largest common divisor" and draw the "largest concentric circles" to jointly promote the high-quality development of the biomedical industry.

During the exhibition, the local core mainstream media Taizhou Daily released a special edition report with the title of "Recbio Industrialization Fruits Mature In Sight" and conducted a one-on-one interview with Dr. Liu Yong. Dr. Liu Yong introduced in detail the company’s exhibiting products, new research and development of new technologies, innovation and application development, and said that as a local enterprise rooted in China Pharmaceutical City, it should set an example to show the new image of Taizhou city, new opportunities for development, and new future of the industry to the world, further expand the channels of international cooperation and exchange, and inject new impetus into the construction of a higher level of China Pharmaceutical City.

As a vaccine company with a full range of new adjuvant R&D and production capabilities, Recbio’s new adjuvant platform has been accumulated for more than ten years, and through continuous investment, it has continuously strengthened the layout of independent intellectual property rights in the field of new adjuvants. The company has applied for more than 20 invention patents in the principles, processes, raw materials, and applications of new adjuvants.

The new adjuvant platform of Recbio has three characteristics: systematization, industrialization, and continuous innovation. Systematic means that the platform can achieve full coverage of the new adjuvant types for human use that have been approved worldwide, forming a "toolbox" and "Arsenal" of vaccine R&D, and the research and development team can match the most appropriate adjuvant types according to the immune protection mechanism of different vaccines. The recombinant shingles vaccine, second-generation HPV vaccine, and recombinant COVID-19 vaccine independently developed by the company are matched with different types of new adjuvants. Industrialization refers to the company’s new adjuvant platform has built three industrialization bases in China Pharmaceutical City, covering three mainstream adjuvant process platforms, and forming an annual production capacity of more than 100 million new adjuvants. Continuous innovation means that the company’s pursuit of adjuvant performance will never stop, and will continue to introduce more and better adjuvant varieties for the next generation of vaccine product pipeline.

Recbio’s new adjuvant platform not only plays a strategic role in supporting self-developed vaccine varieties, but also enables industrial chain partners. Since the beginning of this year, the company has launched "new adjuvant system solutions" for partners, and through deep cooperation from research and development to industrialization, innovative research and development of partners’ vaccine varieties, and promoting the upgrading and iteration of traditional vaccines.

Benefiting from the leading new adjuvant core technology and the near industrialization of the heavy pipeline, the international layout of Recbio is accelerating. Recently, the company signed a strategic cooperation agreement with the Zimbabwe National Biotechnology Authority and the China Research Center of the International Center for Genetic Engineering and Biotechnology (ICGEB) to provide vaccine technology to Zimbabwe. The company is also speeding up cooperation with relevant countries and regions in India, Russia, and Southeast Asia to accelerate the pace of product listing in the local market so that China’s new adjuvant vaccine technology can benefit the broader population in the countries and regions jointly built by the "Belt and Road" as soon as possible.

About Recbio

Founded in 2012, Jiangsu Recbio Technology Co., Ltd. (hereafter referred to as Recbio or the Company; stock code: 2179.HK) is an innovative vaccine company propelled by internally developed technologies. Committed to our mission of " Protect human health with best-in-class vaccines", we have cultivated a robust portfolio of vaccine products with exclusive rights, addressing the substantial unmet needs in the realm of high-impact infectious diseases. Over the course of more than two decades, Recbio has meticulously built three pioneering platforms: a novel adjuvant platform, a protein engineering platform, and an immunological evaluation platform, making us one of the few global companies capable of both developing and manufacturing the complete range of novel adjuvants.

Leveraging the close integration of our three platforms, we are consistently creating promising vaccine candidates. Fueled by these innovative platforms, the Company has forged a high-value portfolio of innovative vaccines, encompassing over ten potential blockbuster varieties. These encompass areas such as cervical cancer, shingles, RSV infection, and other prevalent high-burden diseases, and have emerged as leading products in terms of development and clinical progress in China.

Having been honed and refined over the course of a decade, Recbio is poised to reap the benefits as several products are nearing commercialization.

Forward-looking statements

This Press Release may contain projections, estimates, forecasts, targets, opinions, prospects, results, returns and forward-looking statements with respect to the financial condition, results of operations, capital position, strategy and business of the Group which can be identified by the use of forward-looking terminology such as "may", "will", "should", "expect", "anticipate", "project", "plan", "estimate", "seek", "intend", "target", "believe", "potential" and "reasonably possible" or the negatives thereof or other variations thereon or comparable terminology (collectively, "forward-looking statements"), including the strategic priorities, research and development projects, and any financial, investment and capital targets and any other targets, commitments and ambitions described in writing or verbally herein. Any such forward-looking statements are not a reliable indicator of future performance, as they may involve significant stated or implied assumptions and subjective judgements which may or may not prove to be correct, accurate or complete. There can be no assurance that any of the matters set out in the forward-looking statements are attainable, will actually occur or will be realised or are complete or accurate. The assumptions and judgments may prove to be incorrect, inaccurate or incomplete, and involve known and unknown risks, uncertainties, contingencies and other important actors, many of which are outside the control of the Group. There is also no assurance that the Group may develop or market its core products or other pipeline candidates successfully. Actual achievements, results, performance or other future events or conditions may differ materially from those stated, implied and/or reflected in any forward-looking statements due to a variety of risks, uncertainties and other factors (including without limitation general market conditions, regulatory changes, geopolitical tensions or data limitations and changes). Any such forward-looking statements are based on the beliefs, expectations and opinions of the Group at the date the statements are made, and the Group does not assume, and hereby disclaims, any obligation or duty to update, revise or supplement them if circumstances or management’s beliefs,  expectations or opinions should change. For these reasons, you should not place reliance on, and are expressly cautioned about relying on, any forward-looking statements. No representations or warranties, expressed or implied, are given by  or on behalf of the Group as to the achievement or reasonableness of any projections, estimates, forecasts, targets, commitments, prospects or returns contained herein.

Please refer to the announcements published by the Company on the websites of The Stock Exchange of Hong Kong Limited (www.hkexnew.hk) or of the Company (www.recbio.cn) for further details. If there is any inconsistency between this Presentation and the announcements, the announcements shall prevail.

Jiangsu Recbio Technology Co., Ltd.

Investor Inquiry:
Email: [email protected]
Tel: +86-0523-86818860

Media Inquiry:
Email: [email protected]
Tel: +86-0523-86818860

Related Links:
https://www.recbio.cn/ 

Source : Recbio appeared at the 14th China (Taizhou) International Pharmaceutical Fair

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

CHENGDU, China, Oct. 24, 2023 /PRNewswire/ — Human trophoblastic cell surface antigen 2 (TROP2) exhibits high expression in numerous solid tumors, making it a prominent target in recent oncology studies. The progress in the development of Antibody-Drug Conjugates (ADCs) against  this target has garnered significant interest in recent years. At this year’s European Society for Medical Oncology (ESMO) Congress held in Madrid, Spain from October 20-24, the innovative TROP2-ADC (SKB264, MK-2870) for the treatment of hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic Breast Cancer (mBC) was jointly presented by Kelun-Biotech and MSD. The results of a Phase I/II single-arm, basket study (Abstract No. 380MO) were delivered orally, confirming the manageable safety profile and potent antitumor activity of SKB264 (MK-2870) in patients with HR+/HER2- metastatic breast cancer. Professor Yongmei Yin represented the study team in delivering a plenary report on this promising  study and its primary outcomes.

Study Background

TROP2  overexpression frequently occurs in HR+/HER2- metastatic breast cancer and is correlated with unfavorable patient prognosis. SKB264 (MK-2870) is an ingeniously designed ADC targeting TROP2, which is composed of a humanized anti-TROP2 monoclonal antibodysecurely attached to a small molecule toxin T030 (a novel topoisomerase I inhibitor) via an optimized CL2A linker (employing methanesulfonylpyrimidine for irreversible conjugation between the linker and antibody). The Drug-to-Antibody Ratio (DAR) averages as high as 7.4. Importantly, this is the inaugural public reporting of SKB264 (MK-2870)   being used in a Phase II cohort study for patients with HR+/HER2- metastatic Breast Cancer.

Study Methods

Patients with HR+/HER2- metastatic breast cancer (inclusive of low and null HER2 expression) were administered  SKB264 at a dosage of 5 mg/kg biweekly, continuing until the emergence of either disease progression or intolerable toxicity. The study incorporated patients who had previously experienced treatment failure with endocrine therapy and had undergone at least one round of chemotherapy. Tumor evaluations were conducted by the investigator every 8 weeks in accordance with RECIST v1.1.

Study Results

As of April 12, 2023, the study has enrolled a total of 41 patients, with a median age of 50 years. Among these patients, 61% have an ECOG PS score of 1. The study’s median follow-up duration was 8.2 months.

The primary adverse reactions predominantly involved hematological toxicities. The most frequently observed ≥ Grade 3 Treatment-Related Adverse Events (TRAEs) included decreased neutrophil count (36.6%), reduced white blood cell count (22%), anemia (14.6%), and diminished platelet count (9.8%). The majority of these hematological toxicities manifested within the initial two months of treatment and were resolved without the need for transfusion, following administration of G-CSF or erythropoietin. The dosage was reduced in 17.1% (7/41) of patients due to TRAEs, with no instances of medication discontinuation or death resulting from  TRAEs. The occurrence  of gastrointestinal TRAEs was minimal, and there were no observed instances of drug-associated neuropathy or interstitial lung disease/pneumonia.

Among the 38 patients evaluable for efficacy, 71% demonstrated low HER2 expression, 47% demonstrated primary endocrine drug resistance, and 79% had previously undergone ≥2 lines of chemotherapy for metastatic breast cancer. All patients had been treated with taxane-based chemotherapydrugs, and 65.8% had previously received CDK4/6 inhibitor treatment. The observed Objective Response Rate (ORR) stood at 36.8%, with the Disease Control Rate (DCR) registering at 89.5%. The rate of duration of  response (DoR) over a 6-month period was 80%, and the median Progression-Free Survival (PFS) spanned 11.1 months. Most notably, all subgroups experienced benefits, encompassing patients with low and null HER2 expression, primary and secondary endocrine drug resistance, and those with or without prior use of CDK4/6 inhibitors.

Study Conclusion

SKB264 (MK-2870) has demonstrated manageable safety profiles and promising antitumor activity in patients with HR+/HER2- metastatic breast cancer. Two Phase III clinical studies are presently being planned for patients with HR+/HER2- metastatic breast cancer: one domestic study will focus on on patients who have undergone at least one line of chemotherapy in the metastatic setting, and the other is planned to be a global  study involving patients who have not previously been treated with chemotherapy in the metastatic setting.

Summary
Previously, SKB264 (MK-2870) demonstrated promising efficacy and manageable safety profiles in patients with metastatic Triple-Negative Breast Cancer (TNBC) and Non-Small Cell Lung Cancer (NSCLC) who had undergone multiple prior lines of treatment. At this year’s ESMO conference, it has now also demonstrated significant therapeutic potential in patients with HR+/HER2- metastatic breast cancer, undoubtedly bolstering confidence for the initiation of further series of studies in related fields.

During the 2022 SABCS Annual Conference, SKB264 (MK-2870) released  data from a Phase II extension study conducted on patients suffering from locally advanced or metastatic TNBC. Among the 55 patients eligible for efficacy evaluation, the ORR was 43.6%, and the DCR was 80%. Notably, in patients exhibiting high TROP2 expression, the ORR was 55.2%. The median Duration of Response (mDoR) was 11.5 months, the median Progression-Free Survival (PFS) was 5.7 months, the median Overall Survival (mOS) was 14.6 months, and the overall survival rate at 12 months was 66.4%.

During the 2023 ASCO Annual Conference, SKB264 (MK-2870) released  data from a Phase II extension study conducted on patients with previously treated locally advanced or metastatic NSCLC. The therapeutic efficacy was evaluable in 39 patients, exhibiting an ORR of 43.6%, a DCR of 94.9%, a mDoR of 9.3 months, a 6-month DoR of 77%, and a 12-month Overall Survival (OS) rate of 70.6%. In the subgroup analysis of patients  with EGFR mutations, the ORR was 60%, the DCR reached 100%, the mDoR was 9.3 months, the mPFS was 11.1 months, and the 12-month Overall Survival (OS) rate stood at 80.7%.

Based on the currently published study data,  SKB264 (MK-2870)stands out as one of the most promising TROP-ADCs  for the treatment of advanced triple-negative breast cancer, advanced HR+HER2- breast cancer, and non-small cell lung cancer  with EGFR mutations unresponsive to TKI treatment.

Based on compelling study data in breast and lung cancer, SKB264 (MK-2870) has been granted three breakthrough therapy designations by the CDE. These include its use as a monotherapy for locally advanced or metastatic TNBC, for locally advanced or metastatic EGFR-mutated Non-Small Cell Lung Cancer (EGFRm NSCLC) unresponsive to EGFR-TKI treatment, and for locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2-negative (HER2-) breast cancer in patients who have previously undergone at least two lines of systemic chemotherapy.

In the field of breast cancer, the Phase III registrational study of SKB264 (MK-2870) as a standalone treatment for patients with locally advanced or metastatic triple-negative breast cancer, who have previously undergone two or more lines of systemic treatment, has achieved its primary study endpoint. Based on the study results, an application for market approval in China is expected to be submitted to CDE by the end of this year. A Phase III registrational study for the use of SKB264 (MK-2870) as a monotherapy in patients with locally advanced or metastatic HR+HER2- breast cancer, who have previously experienced at least one unsuccessful round of chemotherapy, has also received CDE approval to proceed. A Phase II study investigating the use of SKB264 (MK-2870) in conjunction with KL-A167 (an anti-PD-L1 monoclonal antibody) as a first-line treatment for patients with HER2-negative breast cancer is also currently underway. Additionally, several registrational studies in NSCLC are advancing rapidly, including  active exploration in  combination therapy regimens  and the applications in other solid tumors. There is undoubtedly much anticipation for the release of further clinical study findings, which may further demonstrate  the potential of SKB264 (MK-2870) to be a beacon of hope for cancer patients worldwide!

Source : Based on recent data presented at 2023 ESMO, the innovative TROP2 ADC SKB264 (MK-2870) shows promising prospects for the treatment of patients with HR+/HER2- metastatic breast cancer who have undergone multiple prior lines of therapy , and its clinical development in other solid tumors is also advancing steadily

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

Macau Junior Golf Association members learn from Minjee Lee, Lydia Ko, Minwoo Lee, and Collin Morikawa

MACAO, Oct. 24, 2023 /PRNewswire/ — Sands China hosted four renowned professional golfers at the Front Lawn (between The Parisian Macao and the Four Seasons Hotel Macao Cotai Strip) and at The Venetian® Macao Monday for Sands Golf Day, where they led a skills challenge with 16 young local golfers aged 7-15 from the Macau Junior Golf Association.

Professional golfer Minjee Lee (right) mentors a local junior golfer from the Macau Junior Golf Association during the Sands Golf Day event Monday at the Front Lawn (between The Parisian Macao and the Four Seasons Hotel Macao Cotai Strip). The Sands China event offered its young participants a unique platform of interaction, inspiration, and mentorship with four accomplished golf pros.

The event offered the young participants a unique platform of interaction, inspiration, and mentorship with the four accomplished golf pros: Minjee Lee, Lydia Ko, Minwoo Lee, and Collin Morikawa.

Minjee Lee is a ten-time LPGA Tour winner, including two Majors: the Evian Championship and the U.S. Women’s Open. An Australian of Korean heritage, she is also the first female brand ambassador for Las Vegas Sands Corp.

Lydia Ko is former Ladies Professional Golf World Number 1, and was the youngest player to reach that milestone. The Korean-born New Zealander is a 19-time LPGA Tour winner, including two Majors.

Minwoo Lee is the 2023 Macao Open champion, winning by setting a new tournament record of a four-round aggregate of 30 under par. The brother of Minjee Lee, he is a star player in the European Tour and the Asian Tour.

Collin Morikawa is a two-time Ryder Cup player for the U.S., a six-time PGA tour winner, and a two-time Major champion. An American of Chinese and Japanese descent, he became the first player in history to win on two Major championship debuts.

"At Sands China, we are committed to supporting the development of local sports talent and nurturing the growth of young athletes," said Dr. Wilfred Wong, president of Sands China Ltd. "With community events like this, we bring together accomplished sports professionals and aspiring athletes from our community. Our aim is to provide a unique platform for interaction and mentorship, motivating young athletes to pursue their goals with unwavering determination, and we hope to help them realise their full potential and contribute to the rich sporting legacy of our city. We are additionally delighted to use this opportunity to raise awareness of vulnerable groups with a donation to two local charitable associations – the Macau Deaf Association and Orbis Macau."

Minjee Lee said: "I am thrilled to be part of this event to inspire young people and ignite their passion for sports, while supporting two local charities. The opportunity to demonstrate and share my love for golf with junior players in Macao is a privilege on its own; seeing their enthusiasm and potential is doubly rewarding. I am grateful to Sands China for giving me this opportunity to spread joy through golf and make a positive impact on people’s lives in the Macao community."

During the first part of Monday’s event, the Front Lawn Challenge, the professional golfers demonstrated their accuracy at a lively skills challenge, where they attempted to hit long-distance shots at designated targets, with the participation of the amateur young golfers adding excitement to the event.

It was followed by the Long Putt Skills Challenge, where the 16 young golfers were divided into four groups, with each group led by a pro golfer. Each group played on behalf of either the Macau Deaf Association or Orbis Macau. At the end of the challenge, Sands China donated a total of MOP 100,000 to the two organisations, based on the results of the friendly competition.

Sands Golf Day is the latest example of Sands China’s parent company, Las Vegas Sands, helping bring sporting events and professional athletes to Macao. Sands has demonstrated its commitment to increasing access to such opportunities for young people in Macao through its partnerships with ambassadors like British football icon David Beckham, and now Minjee Lee.

For high resolution images, please access the following:
https://we.tl/t-3lQQmucZHg
(Link valid until Oct. 30, 2023)

About Sands China Ltd.

Sands China Ltd. (Sands China or the Company) is incorporated in the Cayman Islands with limited liability and is listed on The Stock Exchange of Hong Kong Limited (HKEx: 1928). Sands China is the largest operator of integrated resorts in Macao. The Company’s integrated resorts on the Cotai Strip comprise The Venetian® Macao, The Plaza® Macao, The Parisian Macao and The Londoner® Macao. The Company also owns and operates Sands® Macao on the Macao peninsula. The Company’s portfolio features a diversified mix of leisure and business attractions and transportation operations, including large meeting and convention facilities; a wide range of restaurants; shopping malls; world-class entertainment at the Cotai Arena, The Londoner Arena, The Venetian Theatre, The Parisian Theatre, the Londoner Theatre and the Sands Theatre; and a high-speed Cotai Water Jet ferry service between Hong Kong and Macao. The Company’s Cotai Strip portfolio has the goal of contributing to Macao’s transformation into a world centre of tourism and leisure. Sands China is a subsidiary of global resort developer Las Vegas Sands Corp. (NYSE: LVS).

For more information, please visit www.sandschina.com.

Media contacts:
Corporate Communications, Venetian Macau Limited
Mabel Wu
Tel: +853 8118 2268
Email: [email protected] 

Jesse Chiang
Tel: +853 8118 2054
Email: [email protected]

Professional golfer Minjee Lee, Lydia Ko, Minwoo Lee, and Collin Morikawa mentor local junior golfers from the Macau Junior Golf Association during the Sands Golf Day event Monday at the Front Lawn (between The Parisian Macao and the Four Seasons Hotel Macao Cotai Strip).

Professional golfer Collin Morikawa (rear left) mentors local junior golfers from the Macau Junior Golf Association during the Sands Golf Day event Monday at the Front Lawn (between The Parisian Macao and the Four Seasons Hotel Macao Cotai Strip).

Professional golfer Lydia Ko (right) and local junior golfers participate in the Long Putt Skills Challenge during the Sands Golf Day event Monday at The Venetian Macao.

Professional golfers Minjee Lee, Lydia Ko, Minwoo Lee, and Collin Morikawa join local junior golfers from the Macau Junior Golf Association and guests of honour for the Sands Golf Day event Monday at The Venetian Macao.

Source : Young Local Golfers Play with 4 Pro Champions at Sands Golf Day

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

YANTAI, China, Oct. 24, 2023 /PRNewswire/ — On the afternoon of October 22nd, the 21st International Fruit Vegetable Food Expo, jointly organized by the Shandong Provincial People’s Government and the Ministry of Commerce of China, and hosted by the Yantai Municipal People’s Government and the Shandong Provincial Department of Commerce, successfully concluded at the Yantai International Expo Center, presenting a grand feast of fruits and vegetables to the audience. Over the past twenty-one years, the Expo has continuously refined and upgraded alongside the industry, once again showcasing Yantai’s charm as the "Capital of Food in China" to the industry.

Laiyang pear, the star product in the Laiyang exhibition hall, was particularly eye-catching with its thin skin, abundant juice, and large size.

The exhibition area of this Expo covers an area of 20,000 square meters and has attracted participation from over 500 well-known companies both at home and abroad, according to Yantai Municipal People’s Government Information Office. Various cities and counties at prefecture level in Shandong, such as Qixia, Laiyang, Fushan, Longkou, Laizhou, Zhaoyuan, Haiyang and so on, have organized special regional exhibition groups to participate in this event, showcasing an intensive display of distinctive high-quality products and technologies. This has further enhanced the level of professionalism at the Expo.

The three-day fruit and vegetable expo event has attracted a large crowd on-site, with a wide variety of high-quality products. The fresh fruits and vegetables, pre-made dishes, exhibits related to smart agriculture, and various exhibitions have dazzled the eyes, providing a visual feast. The China-ASEAN Agricultural Development and Food Safety Cooperation Conference revolved around topics such as edible agricultural product standards, sustainable trade development, promoting green growth, and international trade, facilitating discussions and sharing of insights. Activities such as the "Fruit Creative Show and Fantasies about Vegetables" DIY and the Yantai Intangible Cultural Heritage Collection have collectively crafted a splendid visual spectacle featuring fruits and vegetables, delighting the audience in attendance.

The 21st International Fruit Vegetable Food Expo is a combination of Expo (fruit & vegetable exhibitions), conference (concurrent activities), competition (fruit and vegetable DIY activities), and art (intangible cultural heritage exhibition). It has attracted exhibitors by professional planning and operation and brought together elites in the industry through advanced technology and product promotion activities, providing a one-stop service platform for upstream and downstream enterprises in the fruit and vegetable food industry chain.

Image Attachments Links:

   Link: https://iop.asianetnews.net/view-attachment?attach-id=442789

   Caption: Laiyang pear, the star product in the Laiyang exhibition hall, was particularly eye-catching with its thin skin, abundant juice, and large size.

   Link: https://iop.asianetnews.net/view-attachment?attach-id=442794

   Caption: Exhibitors have displayed a dazzling array of fruits and vegetables, attracting numerous buyers to come and make their selections.

   Link: https://iop.asianetnews.net/view-attachment?attach-id=442795

   Caption: Chongquan, the President of China Society for World Trade Organization Studies, and guests, were appreciating Qixia apples at the Qixia Exhibition Hall.

   Link: https://iop.asianetnews.net/view-attachment?attach-id=442796

   Caption: Yantai’s specialty food has attracted a large number of spectators to stop.

Exhibitors have displayed a dazzling array of fruits and vegetables, attracting numerous buyers to come and make their selections.

Chongquan, the President of China Society for World Trade Organization Studies, and guests, were appreciating Qixia apples at the Qixia Exhibition Hall.

Yantai’s specialty food has attracted a large number of spectators to stop.

Source : The 21st International Fruit Vegetable Food Expo came to a successful conclusion

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network